Background. Carbapenem-resistant Acinetobacter baumanii (CRAB) is an infectious disease threat with limited treatment options. Statewide CRAB reporting and isolate submission has been mandated in Connecticut (CT) since 2017, which allowed the creation of a statewide CRAB antibiogram to assist with empiric treatment options for CRAB.
Methods. Clinical CRAB isolates from 2017 through the first quarter of 2019 underwent carbapenemase and expanded susceptibility testing at the CT State Public Health Laboratory or the Antibiotic Resistance Laboratory Network regional lab for carbapenemase and expanded susceptibility testing. Susceptibility testing was done by broth microdilution and disk diffusion, and interpreted using Clinical and Laboratory Standards Institute breakpoints. Carbapenemase producers were detected by the modified carbapenem inactivation method. Polymerase chain reaction testing identified carbapenemase genes.
Results. Of the 64 CRAB isolates submitted, 40 remained after confirmation of carbapenem resistance, i.e., resistance to at least one carbapenem, and deduplication of patients. Of these, 19 were carbapenemase producers (CP), and 21 were non-carpabenemase producers (Non-CP). All isolates were non-susceptible to cefepime, ceftazidime, levofloxacin and all carbapenems. Colistin susceptibilities were available for 33 isolates, 32 (97%) of which were susceptible. Tobramycin susceptibilities were available for 31 isolates, only 10 (32%) of which were susceptible. Of the CP, all 15 were susceptible to colistin, but only 2 (14%) were susceptible to tobramycin. Of the Non-CP, 16 (89%) were susceptible to colistin, and 8 (47%) were susceptible to tobramycin. Most CRABs had a tigecycline minimum inhibitory concentration (MIC) of ≤2 μg/mL, with a higher proportion of Non-CP with lower MIC values than CP.
Conclusion. CRAB shows resistance to all carbapenems, and most non-carbapenem antibiotics except colistin and in rare circumstances tobramycin. Most CRAB isolates had tigecycline MICs of ≤2 μg/mL. The statewide antibiogram illustrates the lack of approved antibiotics for the treatment of CRAB, underscoring the importance of further antibiotic development for CRAB treatment.
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